drugset / Trial / NCT00295958
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery
Phase 2
Completed
26 enrolled
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: The LMB-2 immunotoxin can find tumor cells and kill them without harming normal cells. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving LMB-2 immunotoxin together with vaccine therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving LMB-2 immunotoxin together with vaccine therapy works in treating patients with metastatic melanoma that cannot be removed by surgery.
Timeline
- Start
- 2005-12
- Primary completion
- 2006-06
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LMB-2 | Protein / enzyme biologic | — | Intravenous |
| Subject | MART-1 antigen | Vaccine | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |